Role of inflammasome activation in lupus nephritis ((2)-P24)

炎症小体激活在狼疮性肾炎中的作用 ((2)-P24)

• 批准号: 233460673
• 金额: --
• 依托单位: Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)
• 依托单位国家: 德国
• 项目类别: CRC/Transregios
• 财政年份: 2013
• 资助国家: 德国
• 起止时间: 2012-12-31 至 2019-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/233460673?language=en
• 关键词: Role; inflammasome; activation; lupus; nephritis

The goal of this project is to elucidate the role of inflammasome activation in lupus nephritis that is mediated by e.g. immune complex deposition in the glomeruli, local IL-1¿ production and TLR activation causing glomerular sclerosis. Using the pristane-induced mouse model for SLE, we will determine if inflammasome activation in specific cell types and at specific disease steps is important. A novel and potent small molecule inhibitor of NLRP3 will be used to assess efficacy of a novel treatment approach in our preclinical model. We will also address the question if renal MDSC are important regulators in glomerular sclerosis and translational aspects will focus on the identification of novel biomarkers for the determination of inflammasome activation during lupus disease progression in mouse and human samples.

该项目的目标是阐明炎症小体激活在狼疮性肾炎中的作用，该作用是由例如狼疮性肾炎介导的。免疫复合物在肾小球沉积、局部IL-1¿产生和TLR激活导致肾小球硬化。使用降植烷诱导的 SLE 小鼠模型，我们将确定特定细胞类型和特定疾病步骤中炎症小体的激活是否重要。 NLRP3 的新型有效小分子抑制剂将用于评估我们的临床前模型中新型治疗方法的疗效。我们还将解决肾 MDSC 是否是肾小球硬化的重要调节因子的问题，翻译方面将重点关注鉴定新的生物标志物，用于确定小鼠和人类样本中狼疮疾病进展期间炎症小体的激活。